Dragonfly Therapeutics, Inc. added Robin Edwards and David Ferry to its clinical leadership team. Edwards will oversee translational medicine and Ferry will run clinical development in oncology.

Edwards was previously global head of translational sciences at Daiichi Sankyo and head of translational pathology at Bristol Myers Squibb, while Ferry, was previously head of GI Oncology at Eli Lilly.

“The encouraging clinical results we are seeing with our three internally owned drug programs, and our plan to rapidly expand our clinical footprint over the next several years, are leading us to double the size of our clinical team in 2023,” said Bill Haney, Dragonfly’s CEO, and co-founder. “Robin and David, who will run Translational Medicine and Clinical Development in Oncology, respectively, are fantastic additions to the Dragonfly team.”

“We are delighted that Robin and David have joined Dragonfly,” said Joe Eid, president of R&D at Dragonfly. “Their impressive accomplishments and deep experience in drug development will be invaluable in managing our novel drug candidates in the clinic, supporting our partner programs with existing collaborators BMS, Merck, AbbVie and Gilead – which presently include three Dragonfly developed TriNKET programs that are in the clinic – and expanding our portfolio of wholly-owned clinical assets.”

Dragonfly’s growing clinical pipeline includes a Phase 1/2 Study of DF1001, an immune modulating TriNKET targeting HER2, a Phase 1 study of its novel interleukin-12 (IL12) cyotkine DF6002, a Phase 1 study of its DF9001 TriNKET targeting EGFR for solid tumor cancers, and a fourth wholly owned cytokine program planned to file IND this year. Including partnered assets, there are presently six total Dragonfly-developed drugs in clinical studies, worldwide.